Nymox Pharma reports positive Phase III trials for its prostate drug-candidate

21 August 2015

Biopharmaceutical company Nymox Pharmaceutical (Nasdaq: NYMX) said its late stage trial for its drug candidate to treat prostate enlargement in older men has met its primary endpoint.

The Canada-based company in a statement said the drug candidate, fexapotide triflutate (NX-1207) for benign prostatic hyperplasia (BPH) showed a safety profile with no evidence of drug-related short-term or long-term toxicity nor any significant related molecular side in Phase III trials.

Nymox Pharmaceutical now plans to file for regulatory approvals for fexapotide triflutate.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK